Vuzix Corp Reports Material Impairment

TL;DR

VUZIX just filed an 8-K for a material impairment. Big asset write-down incoming?

AI Summary

On July 1, 2024, Vuzix Corporation filed an 8-K report indicating a material impairment. The company, incorporated in Delaware with its principal executive offices in West Henrietta, New York, is reporting this event as of July 1, 2024. The filing does not specify the exact nature or financial impact of the impairment.

Why It Matters

A material impairment suggests a significant negative revaluation of company assets, which could impact future profitability and financial health.

Risk Assessment

Risk Level: medium — Material impairments can signal underlying business issues or asset overvaluation, requiring further investigation into the specific cause and financial impact.

Key Players & Entities

• Vuzix Corporation (company) — Registrant
• July 1, 2024 (date) — Date of earliest event reported
• 25 Hendrix Road, Suite A, West Henrietta, New York 14586 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — h registered: Common Stock, par value $0.001 VUZI Nasdaq Capital Market Indica
• $32.2 m — inciples, up to the aggregate amount of $32.2 million, including $26.5 million for tech
• $26.5 million — gate amount of $32.2 million, including $26.5 million for technology licenses, and $5.7 milli
• $5.7 million — .5 million for technology licenses, and $5.7 million for the Company's investment in Atomist

Filing Documents

• tm2418867d1_8k.htm (8-K) — 24KB
• 0001104659-24-077671.txt ( ) — 193KB
• vuzi-20240701.xsd (EX-101.SCH) — 3KB
• vuzi-20240701_lab.xml (EX-101.LAB) — 33KB
• vuzi-20240701_pre.xml (EX-101.PRE) — 22KB
• tm2418867d1_8k_htm.xml (XML) — 4KB

06 Material Impairments

Item 2.06 Material Impairments. Vuzix Corporation (the "Company") made the decision to cease further funding its development activities with Atomistic SAS ("Atomistic") under the license agreement, dated December 16, 2022, among the Company, Atomistic, and Atomistic's two principals (the "License Agreement"). The Company is supportive of the technical path of the technologies that were subject to the License Agreement and the potential future of Atomistic. The Company's decision gave Atomistic the right under the License Agreement to terminate the Granted License (as defined under the License Agreement), which right Atomistic exercised on July 1, 2024. Notwithstanding the termination of the Granted License, the Company will be entitled to certain License Royalties (as defined under the License Agreement) from Atomistic if it licenses the technology that was the subject of the Granted License. The Company will retain an equity interest in Atomistic, the right to appoint a member to the Atomistic board of directors and certain other rights as an equity owner pursuant to the stock purchase agreement and shareholders' agreement entered into in connection with the License Agreement. The Company's equity interest in Atomistic entitles it to a preferential allocation to 49% of the distributable amounts in the event of a liquidation event of Atomistic. As a result of the termination of the Granted License, on July 1, 2024, the Company's chief financial officer concluded that the Company will be required to incur a material charge for impairment under generally accepted accounting principles, up to the aggregate amount of $32.2 million, including $26.5 million for technology licenses, and $5.7 million for the Company's investment in Atomistic. The Company anticipates that the impairment charge will not result in any future cash expenditures. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 3, 2024 VUZIX CORPORATION By: /s/ Grant Russell Grant Russell Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR